B型ナトリウレチンペプチドの有機ミトラル反吐:決定因子と結果への影響
Delphine Detaint1, David Messika-Zeitoun, Jean-François Avierinos
1Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.
Circulation
|May 11, 2005
まとめ
B型ナトリウレチンペプチド (BNP) レベルは,オーガニック・ミトラル・リグルジテーション (MR) で,MRの重症度ではなく,心臓損傷を反映しています. 高いBNPは,MRの患者でより悪い結果を予測し,リスク評価を助けます.
科学分野:
- 心臓病学 心臓病学
- バイオマーカー バイオマーカー
- 心不全による心不全.
背景:
- B型ナトリウレチンペプチド (BNP) アクティベーションは,様々な心臓病における悪い結果の既知の予測因子です.
- しかし,有機ミトラル排泄 (MR) でのBNPの特定の決定因子と予後値は,ほとんど不明のままです.
研究 の 目的:
- 慢性有機MR患者のBNPレベルに影響を与える要因を調査する.
- この患者集団における有害な結果の予測におけるBNPの予後的意義を評価する.
主な方法:
- 慢性有機MRを患っている124人の患者の将来的な登録.
- BNPレベル,MRの重症度,左心房 (LV) の改造,そして左心房 (LA) の体積の測定.
- 生存率と死亡と心不全の統合エンドポイントを含む長期的なアウトカム分析.
主要な成果:
- BNPの独立した決定因子には,年齢,性別,LVエンドシストリックボリューム指数,LAボリューム,心房動,および症状が含まれていた.
- BNP濃度が高い患者 (≥31 pg/mL) は,生存率が著しく低下し,5年後に死亡率や心不全率が高かった.
- BNPは,臨床的およびエコーカルディオグラフィの要因を調整した後でも,独立して死亡率と死亡または心不全の統合エンドポイントを予測しました.
結論:
- オーガニックMRにおけるBNPの活性化は,MRの程度ではなく,主に心室と心房の影響を反映しています.
- オーガニックMRの患者におけるBNP濃度の上昇は,保守的な管理下での不良臨床イベントの独立した予測因子である.
- BNPは,MRの結果の重症性を評価し,不良の結果を予測するための貴重なバイオマーカーとして機能し,臨床評価とリスク分層化におけるその使用を支持しています.
さらに関連する動画
関連する概念動画
01:27Mitral Valve Prolapse I: Introduction
1.1K
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
1.1K
01:20Mitral Regurgitation I: Introduction
1.3K
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.3K
01:25Mitral Regurgitation III: Medical Management
686
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
686
01:28Mitral Regurgitation IV: Nursing Management
602
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
602
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
557
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
557
01:26Mitral Stenosis III: Medical Management
535
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535